Skip to main content
Holiday Sale — Get 40% off Vantage for yourself or as a gift
Published loading...Updated

Shaping The Future of Obesity Care A Discussion with Annegret Van der Aa

Drug developers have long pursued the elusive goal of safely increasing energy expenditure to treat metabolic conditions and obesity. Leiden-based Cantoni Therapeutics is hoping to achieve this goal with its novel small molecule inhibitors of nicotinamide N-methyltransferase (NNMT), which have the potential to treat obesity and improve metabolism without loss of muscle mass. The promise of the technology and pathway is something that attracted A…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Inside Precision Medicine broke the news in on Tuesday, December 9, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal